

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

WATSON LABORATORIES, INC.

Petitioner

v.

UNITED THERAPEUTICS CORP.

Patent Owner

Cases¹ IPR2017-01621; Patent 9,358,240
IPR 2017-01622; Patent 9,339,507

DECLARATION OF DEAN BUNCE

¹ The word-for-word identical paper is filed in each proceeding identified in the heading.

I, Dean Bunce, hereby declare as follows:

1. I am currently Executive Vice President of Regulatory Affairs at United Therapeutics Corporation (“UTC”).
2. I have been involved in regulatory affairs and compliance at UTC since 1999. I currently oversee all interactions of UTC with regulatory agencies, including the Food and Drug Administration (“FDA”). I was ultimately responsible for the New Drug Application (“NDA”) and supplements thereto for UTC’s Tyvaso® product.
3. Exhibit 2049 is a true and correct copy of excerpts of the Tyvaso® NDA Integrated Summary of Efficacy (ISE). This is a document created in the regular course of UTC’s business and was submitted to FDA as part of the process of obtaining regulatory approval to market Tyvaso® in the United States.
4. Exhibit 2050 is a true and correct copy of the Clinical Investigation Report Synopsis for Study LRX-INH-0004. This is a document created in the regular course of UTC’s business and was submitted to FDA as part of the process of obtaining regulatory approval to market Tyvaso® in the United States.
5. Exhibit 2051 is a true and correct copy of the Clinical Investigation Report Synopsis for Study LRX-INH-0007. This is a document created in the regular course of UTC’s business and was submitted to FDA as part of the process of obtaining regulatory approval to market Tyvaso® in the United States.

6. Exhibits 2049-2051 are records made from information regularly kept and maintained by UTC in the course of its regular clinical testing activities and thus contain accurate information generated and maintained for the purposes of ensuring compliance with regulatory and best practices requirements. For example, FDA regulations require that a drug sponsor maintain, prepare, and submit accurate information concerning clinical studies. *See e.g.* 21 CFR § 312.33.

7. Exhibit 2083 is a true and correct copy of the TRIUMPH I Clinical Trial Protocol. This is a document created by January 11, 2005 (as reflected on the document) in the regular course of UTC's business and was submitted to FDA as part of the process of obtaining regulatory approval to market Tyvaso® in the United States. More specifically, the protocol was submitted to FDA on March 28, 2005 as part of UTC's original Investigational New Drug Application ("IND") 70,362 for Inhaled Treprostinil. Exhibit 2052 is a true and correct copy of an acknowledgement letter dated April 13, 2005 from FDA acknowledging receipt of IND 70,362 on March 29, 2005.

8. Exhibits 2049 (at page 59) and 2050 (at page 3) state that study LRX-INH-004 was performed in 2003.

9. Exhibits 2049 (at page 61) and 2051 (at page 3) state that LRX-INH-007 was performed in 2003.

10. Exhibit 2083 includes the following information:

- i. Reference to investigator studies in Germany (at pages 17, 21, 25) including “approximately 200 patients in the five investigations, and the 13 patients in the clinical and chronic compassionate use trials”;
- ii. “Treatment doses” indicating the investigational product planned is treprostinil sodium at “600 mcg/mL delivered via an ultrasonic nebulizer (0, 4, 8, 12 hours daily)” with “[e]ach of the four doses will consist of 9 breaths. Each breath will deliver 5 mcg of TRE to the mouthpiece of the nebulizer (emitted dose).” (at page 11); and
- iii. A section on “Clinical Investigations Following Inhalation of Treprostinil” that summarizes five investigations (at pages 22-25):
 1. Investigation 1: Inhalation of Treprostinil and of Iloprost
 2. Investigation 2: Inhalation of treprostinil and of placebo
 3. Investigation 3: Inhalation times of Treprostinil sodium with higher concentrations with reduced inhalation time;
 4. Investigation 4: Inhalation of metacresol free treprostinil;
 5. Investigation 5: Inhalation of Treprostinil and Sildenafil.

11. Exhibit 2083 states that the original Phase II Protocol was finalized by January 11, 2005 with an anticipated First Patient In (FPI) in April/May 2005.

12. As reflected in Exhibit 2049, the first patient was enrolled in the Phase II study in June 2005.

13. The United States National Library of Medicine ClinicalTrials.gov database, which is a database of clinical studies conducted around the world, <https://clinicaltrials.gov/ct2/show/NCT00147199>, gives a date of “June 2005” as the date a first participant was enrolled for TRIUMPH I. A true and correct copy of this record is labelled as Exhibit 2084.

[The remainder of this page is intentionally left blank]

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.